The U.S. Food and Drug Administration (FDA) on Thursday amended the emergency use authorizations (EUAs) for both the Pfizer-BioNTech COVID-19 Vaccine and the Moderna COVID-19 Vaccine to allow for the use of an additional dose in certain immunocompromised individuals.
The late-night announcement Thursday by the FDA applies certain individuals, specifically, solid organ transplant recipients or those who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise requires additional dose.
Other fully vaccinated individuals do not need an additional vaccine dose right now, the agency says.
“Today’s action allows doctors to boost immunity in certain immunocompromised individuals who need extra protection from COVID-19,” Dr. Janet Woodcock, the FDA’s acting commissioner, said in a statement.
The CDC’s Advisory Committee on Immunization Practices will meet on Friday to discuss this issue and offer recommendations.
A global media for the latest news, entertainment, music fashion, and more.
